Association betweenCYP2D6genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association betweenCYP2D6genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 15, Issue 1, Pages 49-60
Publisher
Future Medicine Ltd
Online
2013-12-16
DOI
10.2217/pgs.13.221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
- (2013) Chonlaphat Sukasem et al. Asian Pacific Journal of Cancer Prevention
- CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis
- (2013) Zhiyu Zeng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
- (2012) Jennifer Gjerde et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
- (2012) Hiltrud Brauch et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
- (2011) In Hae Park et al. BREAST CANCER RESEARCH AND TREATMENT
- Pharmacogenetics of anti-estrogen treatment of breast cancer
- (2011) Marzia Del Re et al. CANCER TREATMENT REVIEWS
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
- (2011) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
- (2011) Allan Hackshaw et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Bracelets from cluster bombs
- (2011) Justine Davies LANCET
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
- (2010) Timothy L. Lash et al. ACTA ONCOLOGICA
- Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
- (2010) Bostjan Seruga et al. BREAST CANCER RESEARCH AND TREATMENT
- Orally administered Endoxifen is a new therapeutic agent for breast cancer
- (2010) Ateeq Ahmad et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
- (2010) Alastair M. Thompson et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact ofCYP2D6*4genotype on progression free survival in tamoxifen breast cancer treatment
- (2010) Julia Carolin Stingl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response
- (2010) Kazuma Kiyotani et al. Pharmacogenetics and Genomics
- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- (2009) T. Ramón y Cajal et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
- (2009) T. Toyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
- (2008) W. G. Newman et al. CLINICAL CANCER RESEARCH
- Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)
- (2008) K. Sakuyama et al. DRUG METABOLISM AND DISPOSITION
- Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer
- (2008) L. W. M. Loo et al. GENES CHROMOSOMES & CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started